Vertex Pharmaceuticals Aktie News

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Alphabet's advertising, cloud, and AI businesses are booming. Vertex is branching out beyond its still-successful core business.

MercadoLibre has tremendous potential in the Latin American e-commerce and fintech markets. TransMedics Group is preparing to expand into Italy and has plenty of room to grow in the U.S. as well.

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets beyond CF.

Healthcare investments tend to be less cyclical than other stocks and help diversify your portfolio. Vertex has a profitable portfolio and promising pipeline, and its growth may be just getting started.

Vertex Pharmaceuticals' monopoly grants it significant pricing power, making it an inflation-resistant company. Mastercard's business is well-adapted to navigate inflationary periods; it also has a terrific dividend program.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi's 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scientific Officer, will participate in a fireside chat on Wednesday, December 3, 2025, at 9:00 a.m. ET. A live webcast of management's remarks will be a...